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Pyrimidine and thienopyrimidine derivatives have attracted a great deal of interest
owing to their medicinal activities (1–4). Pyrimidine derivatives and heterocyclic anne-
lated pyrimidines continue to attract great interest due to the wide variety of interesting
biological activities observed for these compounds, such as anticancer (4), antiviral (5),
antitumor (6), anti-inflammatory (7) and antimicrobial activities (8). Also, the rapid growth
in the literature dealing with the synthesis and biological activity of the thienopyrimi-
dine derivatives prompted us to synthesize new derivatives of fused pyrimidine, thieno-
pyrimidine and thienopyridine derivatives. In our previous work (9, 10), we reported
the behaviour of thienopyrimidine derivatives towards hydrazines, 1,3-diketones, a-ha-
loketones and acids. As part of this work, here we report a new synthesis strategy for
the preparation of functionalized thieno[2,3-d][1,2,4]triazolo[4,5-a]pyrimidines, thieno
[2,3-d][1,3]thiazine and thienopyrimidine derivatives via the reaction of hydrazonyl chlo-
ride and cinnamonitriles with thienopyrimidone and 2-amino-5-isopropyl-thiophene-3-
-carbonitrile.
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5-Methyl-6-phenyl-2-thioxothieno[2,3-d]pyrimidone deri-
vative (2) reacted with hydrazonoyl chloride derivatives
to afford triazolothienopyrimidones 4a–f. Also, acetone-
-1-(2-amino-5-isopropyl-thiophene-3-carbonitrile) (3) re-
acted with functional and bifunctional groups to yield the
corresponding compounds 5–11. The new products showed
anti-inflammatory, analgesic, and ulcerogenic activities
comparable to that of indomethacin and acetylsalicylic
acid, respectively.
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EXPERIMENTAL
All melting points were uncorrected and measured using an Electro-thermal IA
9100 apparatus (Shimadzu, Japan). Microanalytical data were performed with a Vario,
Elementar apparatus (Shimadzu) (Table I). The IR spectra (KBr) were recorded on a
Perkin-Elmer 1650 spectrometer (USA). 1H NMR spectra were determined on a Varian
Mercury (300 MHz) spectrometer (Varian, UK) and chemical shifts were expressed in
ppm relative to SiMe4 as internal standard. Mass spectra were recorded on 70 ev EI Ms-
-QP 1000 EX (Shimadzu) (Table II).
The starting materials 2-amino-4-methyl-5-phenyl-thiophene-3-ethylcarboxylate (1),
5-methyl-6-phenyl-2-thioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-4-one (2) and ac-
etone-1-(2-amino-5-isopropyl-thiophene-3-carbonitrile (3) were prepared according to
Gewald et al. (11). The hydrazonoyl chloride was prepared as reported (12, 13).
Physico-chemical and spectral data of the synthesized compounds are given in Ta-
bles I and II, respectively.
Synthesis of 2-amino-4-methyl-5-phenyl-thiopene-3-ethylcarboxylate (1)
A mixture of 6-methyl-heptane-2,4-dione, ethylcyanoacetate, sulfur and diethyl-
amine was heated (70 °C) under stirring in absolute ethanol for 4 hours, then the mix-
ture was left for 24 hours at 0 °C. The formed solid was collected by filtration, washed




A mixture of compound 1 (0.01 mol) and potassium thiocyanate (0.15 mol) was stir-
red under reflux in dioxane containing 10% HCl for 15 hours. Poured into 200 mL water,
the solid precipitated was filtered off and crystallized from dioxane as yellow powder.
Synthesis of acetone-1-(2-amino-5-isopropyl-thiophene-3-carbonitrile (3)
A mixture of 6-methyl-heptane-2,4-dione, malononitrile, sulfur and diethylamine
was heated (70 C) under stirring in absolute ethanol for 4 hours, then left for 24 hours at
0 C. The formed solid was collected by filtration, washed with absolute ethanol (20 mL),
dried and crystallized from absolute ethanol as yellow crystals.
Synthesis of thieno[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one derivatives (4a–f).
General procedure
A mixture of compound 2 (2.74 g, 0.01 mol) and the appropriate hydrazonoyl chlo-
ride (0.01 mol) was stirred under reflux in dry chloroform (30 mL) with 4 drops of
triethylamine for 5 hours. The solvent was evaporated under reduced pressure. The
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solid produced was washed three times with 30 mL absolute ethanol and crystallized
from an appropriate solvent.
6-Methyl-1,3,7-triphenyl-thieno[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one (4a). – Compo-
und 4a was obtained from 2 (2.74 g, 0.01 mol) and N-phenylbenzene-carbohydrazonoyl
chloride (2.31 g, 0.01 mol) as white needles, and crystallized from dimethylformamide.
3-Acetyl-1-(4-chlorophenyl)-7-phenyl-6-methyl-thieno[2,3-d][1,2,4]triazolo-[4,3-a]pyrimidin-
-5-one (4b). – Compound 4b was obtained from 2 (2.74 g, 0.01 mol) and 2-oxo-N-(4-chlo-
rophenyl)-propane hydrazonoyl chloride (1.96 g, 0.01 mol) as brown powder, and crys-
tallized from dimethylformamide.
3-Acetyl-1-(4-methoxyphenyl)-7-phenyl-6-methyl-thieno[2,3-d][1,2,4]triazolo-[4,3-a]pyrimi-
din-5-one (4c). – Compound 4c was obtained from 2 (2.74 g, 0.01 mol) and 2-oxo-N-(4-
-methoxy-phenyl)-propane hydrazonoyl chloride (1.91 g, 0.01 mol) as green powder, and
crystallized from absolute ethanol.
3-Acetyl-1-(4-nitrophenyl)-7-phenyl-6-methyl-thieno[2,3-d][1,2,4]triazolo[4,3-a] pyrimidin-
-5-one (4d). – Product 4d was obtained from 2 (2.74 g, 0.01 mol) and 2-oxo-N-(4-nitro-
phenyl)-propane hydrazonoyl chloride (2.06 g, 0.01 mol) as pale red crystals, and crys-
tallized from absolute ethanol.
1,7-Diphenyl-6-methyl-thieno[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one-3-ethylcarboxylate
(4e). – Compound 4e was obtained from 2 (2.74 g, 0.01 mol) and chloro-(phenylhydra-
zono)-ethyl acetate (2.27 g, 0.01 mol) as white powder, and crystallized from dimethyl-
formamide.
7-Phenyl-6-methyl-1-(4-tollyl)-thieno[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one-3-ethylcar-
boxylate (4f). – Compound 4f was obtained from 2 (2.74 g, 0.01 mol) and chloro-(4-tolyl-
hydrazono)-ethyl acetate (2.41 g, 0.01 mol) as yellow powder, and crystallized from absolute
ethanol/dioxane.
Synthesis of 6-isopropyl-5-(2-oxo-propyl)-3H-thieno[2,3-d]pyrimidin-4-one (5a)
A mixture of compound 3 (2.22 g, 0.01 mol), formic acid (10 mL) and catalytic
amount of concentrated hydrochloric acid was heated under reflux for 12 hours. The re-
action mixture was allowed to cool to room temperature, poured into water (100 mL).
The formed solid was collected by filtration, washed with absolute ethanol (20 mL),
dried and crystallized from dimethylformamide.
Synthesis of 6-isopropyl-2-methyl-5-(2-oxo-propyl)-3H-thieno[2,3-d]pyrimidin-4-one (5b)
A mixture of 3 (2.22 g, 0.01 mol) and glacial acetic acid (30 mL) was stirred under re-
flux for 12 hours (under TLC analysis). The reaction mixture was allowed to cool to
room temperature and was poured into water (100 mL). The solid thus-formed was col-
lected by filtration, washed with etanol (20 mL), dried and crystallized from dimethyl-
formamide.
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Synthesis of 1-(6-isopropyl-2,4-dithioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidin-
-5-yl)-propan-2-one (6)
A mixture of compound 3 (2.22 g, 0.01 mol) and carbon disulphide (excess 10 mL)
was heated under reflux in absolute ethanolic potassium hydroxide solution for 12 hours.
The reaction mixture was allowed to cool to 0 °C for 3 hours, the deposited precipitate
was filtered off, washed with water (20 mL), dried and crystallized from dioxane.
Synthesis of 1-(4-imino-6-isopropyl-2-thioxo-1,4-dihydro-2H-thieno[2,3-d][1,3]-
-thiazin-5-yl)-propan-2-one (7)
A mixture of compound 3 (2.22 g, 0.01 mol) and carbon disulphide (excess 10 mL)
was heated under reflux on a waterbath (80 °C) in 20 mL pyridine for 8 hours (under
TLC control). The reaction mixture was allowed to cool to 0 °C for 3 hours, the deposited
precipitate was filtered off, washed with absolute ethanol (20 mL), dried and crystalliz-
ed from dioxane.
Synthesis of 4-amino-6-isopropyl-5-(2-oxo-propyl)-1H-thieno[2,3-d]pyrimidin-(2-one
or 2-thione) (8a,b). General procedure
A mixture of compound 3 (2.22 g, 0.01 mol) and urea or thiourea (0.01 mol) was
heated at 180 °C in a test tube on sand-bath for 4 hours. The mixture was allowed to cool
to room temperature; the product was solidified by cooling and addition of absolute eth-
anol (50 mL). The precipitate thus-formed was collected by filtration and crystallized from
an appropriate solvent.
4-Amino-6-isopropyl-5-(2-oxo-propyl)-1H-thieno[2,3-d]pyrimidin-2-one (8a). – Compound
8a was obtained from 3 and urea (0.61 g, 0.01 mol), as dark brown crystals and crystal-
lized from dimethylformamide.
4-Amino-6-isopropyl-5-(2-oxo-propyl)-1H-thieno[2,3-d]pyrimidine-2-thione (8b). – Compound
8b was obtained from 3 and thiourea (0.77 g, 0.01 mol) as brown crystals and crystallized
from dioxane.
Synthesis of 4,6-diamino-2-isopropyl-3-(2-oxo-propyl)-thieno[2,3-b]pyridine-5-carbonitrile (9)
To a solution of 3 (2.22 g, 0.01 mol) in glacial acetic acid (50 mL), malononitrile (0.66 g,
0.01 mol) was added. The reaction mixture was stirred under reflux for 8 hours, cooled
to room temperature, then poured into cold water (100 mL). The solid product was fil-
tered off, washed with water, dried and crystallized from absolute ethanol.
Synthesis of 4-amino-6-hydroxy-2-isopropyl-3-(2-oxo-propyl)-thieno[2,3-b]pyridine-
-5-carbonitrile (10)
A mixture of 3 (2.22 g, 0.01 mol) and ethylcyanoacetate (1.13 g, 0.01 mol) in dry
dixane (50 mL) containing a catalytic amount of triethylamine was stirred under reflux
for 8 hours. The reaction mixture was allowed to cool and poured into cold water (100
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mL) and neutralized with acetic acid. The precipitate was filtered off, washed with wa-
ter, dried and crystallized from dioxane.
Synthesis of N-[3-cyano-5-isopropyl-4-(2-oxo-propyl)-thiophen-2-yl]-formamidic acid
ethyl ester (11a)
A mixture of compound 3 (2.22 g, 0.01 mol) and triethylorthoformate (2.96 g, 20 mmol)
was stirred under reflux in acetic anhydride (30 mL) for 6 hours. The reaction mixture
was allowed to cool to room temperature, poured into cold water (100 mL) and neutral-
ized by ammonia solution. The deposited precipitate was collected by filtration, washed
with water, dried and crystallized from absolute ethanol.
Synthesis of N-[3-cyano-5-isopropyl-4-(2-oxo-propyl)-thiophen-2-yl]-acetimidic acid
ethyl ester (11b)
A mixture of compound 3 (2.22 g, 0.01 mol) and triethylorthoacetate (2.96 g, 20 mmol)
was stirred under reflux in acetic anhydride (30 mL) for 6 hours. The reaction mixture
was allowed to cool to room temperature, poured into cold water (100 mL) and neutral-
ized by ammonia solution. The deposited precipitate was collected by filtration, washed
with water, dried and crystallized from benzene.
Synthesis of N-[3-cyano-5-isopropyl-4-(2-oxo-propyl)-thiophen-2-yl]-formamidine (12)
A mixture of 11a (2.78 g, 0.01 mol) and ammonia solution (35%, 20 mL) was stirred
under reflux in absolute ethanol (20 mL) for 8 hours. The reaction mixture was allowed
to cool to room temperature, poured into cold water (100 mL) and neutrallized by di-
luted hydrochloric acid. The deposited white powder precipitate was collected by filtra-
tion, washed with water, dried and crystallized from absolute ethanol.
Synthesis of 1-(4-amino-6-isopropyl-thieno[2,3-d]pyrimidin-5-yl)-propan-2-one (13)
To a warmed absolute ethanolic sodium ethoxide solution [prepared by dissolving
0.23 g (0.01 mol) sodium metal in 50 mL absolute ethanol], compound 12 (2.49 g, 0.01
mol) was added. The mixture was stirred under reflux for 8 hours. The reaction mixture
was allowed to cool to room temperature, poured into cold water (100 mL) and neutra-




A mixture of 11a (2.78 g, 0.01 mol) and hydrazine hydrate (99–100%) (10 mL) was
stirred in absolute ethanol (20 mL) for 2 hours. The reaction mixture was allowed to cool
to room temperature, poured into cold water (100 mL) and neutralized by acetic acid.
The deposited precipitate was collected by filtration, washed with water, dried and crys-
tallized from dioxane.
399
A.-R. B. A. El-Gazzar et al.: Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic
and ulcerogenic activity, Acta Pharm. 57 (2007) 395–411.
PHARMACOLOGICAL SCREENING
Animals
Both sexes of Swiss albino mice (25–30 g) were used in analgesic activity testing and
adult female Sprague-Dawley rats (150–180 g) were used in anti-inflammatory and ul-
cerogenic testing. International principle and local regulations concerning the care of us-
ed laboratory animals was taken into account (14). The animals had free access to stan-
dard commercial diet and water ad libitum and were kept in rooms maintained at 22 ± 1
°C with a 12 h light/dark cycle.
Anti-inflammatory activity
The method adopted resembles essentially that described by Winter et al. (15). Tween-
-80 (10%, V/V) was selected as vehicle to suspend the standard drug and test compo-
unds. The rats were starved for 18 h prior to the experiment. The animals were weighed,
marked for identification and divided into 14 groups, each containing 6 animals. Edema
was induced in the left hind paw of all rats by subcutaneous injection of 0.1 mL of 1%
(m/V) aqueous carrageenean into their footpads. The 1st group was kept as control and
was given 1.0 mL of the vehicle. The 2nd to 13th groups were orally administered an
aqueous suspension of the synthesized compounds (15 mg kg–1 body mass) 1 hour be-
fore carrageenean injection. The last group (standard) was administered indomethacin
in a dose of 10 mg kg–1 body mass, orally as suspension in 10% Tween 80 (16). The paw
volume of each rat was measured with a mercury plethysmometer, before carrageenean
injection and then hourly for 4 hours post administration of the suspension of synthe-
sized compound in 10% Tween 80.
Analgesic activity
The compounds 4a–f, 5a,b, 6, 7 and 8a,b were selected for investigating their anal-
gesic activity in acetic acid induced writhing response in mice, following the method of
Collier et al. (17). Eighty four mice were divided into 14 groups (six in each) and starved
for 16 h. The 1st group which served as control was orally given distilled water in an ap-
propriate volume. The 2nd to 13th groups received the aqueous suspension of synthe-
sized compounds orally (15 mg kg–1 body mass). The last group received acetylsalicylic
acid orally in a dose of 100 mg kg–1 body mass. After 30 minutes, each mouse was ad-
ministerated 0.7% of an aqueous solution of acetic acid (10 mL kg–1 body mass) and the
mice were then placed in transparent boxes for observation. The number of writhes was
counted for 20 min after acetic acid injection. The number of writhes in each treated
group was compared to that of the control group. The number of writhings was record-
ed and the percentage protection was calculated.
Ulcerogenicity
Ulceration in rats was induced as described by Goel et al. (18). Rats were divided
into 14 groups, of six animals each. The control group of animals was administered only
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1H NMR (d, ppm)
(DMSO-d6)




1.21 (t, 3H, CH3), 2.38 (s, 3H, CH3), 4.01 (q, 2H,
CH2), 7.43–7.52 (m, 5H, phenyl), 8.23 (brs, 2H,
NH2, D2O exchangeable)
2 274 (M+), (100) 3153 (NH)
1675 (C=O)
2,40 (s, 3H, CH3), 7.51 (m, 5H, phenyl), 12.45 (s,
1H, NH, D2O exchangeable), 13.50 (s, 1H, NH,
D2O exchangeable)
3 222 (M+) (100) 3400 (brs, NH2)
1704 (C=O)
2217 (CN)
1.00 (d, 6H, 2CH3), 2.05 (Septet, 1H, CH), 2.40 (s,
3H, CH3), 2.50 (s, 2H, CH2), 13.30 (brs, 1H, NH,
D2O exchangable)
4a 434 (M+) (100)
357 (M+-77) (28)
1686 (C=O) 2.11 (s, 3H, CH3), 7.20–7.30 (m, 6H, phenyl), 7.40–





2.13 (s, 3H, CH3), 2.62 (s, 3H, CH3), 7.10–7.15 (d,
2H, phenyl), 7.30–7.35 (m, 2H, phenyl), 7.42–7.44






2.11 (s, 3H, CH3), 2.64 (s, 3H, CH3), 3.88 (s, 3H,
OCH3), 7.15–7.20 (d, 2H, p-sub-pheny), 7.24–7.30
(m, 3H, phenyl), 7.47–7.56 (m, 2H, phenyl), 7.59–
7.63 (d, 2H, phenyl)





2.14 (s, 3H, CH3), 2.80 (s, 3H, CH3), 7.16–7.22 (d,
2H, pheny), 7.26–7.35 (m, 3H, phenyl), 7.51–7.57
(m, 2H, phenyl), 7.56–7.60 (d, 2H, phenyl)
4e 430 (M+) (100) 1714, 1689
(2C=O)
1.27 (t, 3H, CH3), 2.13 (s, 3H, CH3), 4.35 (q, 2H,
CH2), 7.25–7.30 (m, 6H, pheny), 7.40–7.75 (m, 4H,
phenyl)





1.28 (t, 3H, CH3), 2.10 (s, 3H, CH3), 2.35 (s, 3H,
CH3), 4.38 (q, 2H, CH2), 7.12–7.16 (d, 2H, phenyl),
7.25–7.35 (m, 3H, pheny), 7.40–7.51 (m, 2H, phe-
nyl), 8.00–8.05 (d, 2H, phenyl)
5a 250 (M+) (100) 3355 (brs, NH)
1705, 1688
(2C=O)
1.02 (d, 6H, 2CH3), 2.07 (Septet, 1H, CH), 2.41 (s,
3H, CH3), 2.52 (s, 2H, CH2), 8.21 (s, 1H, pyrimi-
dine proton), 13.10 (brs, 1H, NH, D2O exchan-
gable)
5b 264 (M+) (100) 3316 (brs, NH)
1700, 1678
(2C=O)
1.01 (d, 6H, 2CH3), 2.06 (Septet, 1H, CH), 2,23 (s,
3H, CH3), 2.42 (s, 3H, CH3), 2.48 (s, 2H, CH2), 8.21
(s, 1H, pyrimidine proton), 13.10 (brs, 1H, NH)




1.00 (d, 6H, 2CH3), 2.05 (Septet, 1H, CH), 2.40 (s,
3H, CH3), 2.50 (s, 2H, CH2), 8.90 (brs, 1H, NH,
D2O exchangeable), 13.10 (brs, 1H, NH)






1.00 (d, 6H, 2CH3), 2.04 (Septet, 1H, CH), 2.38 (s,
3H, CH3), 2.50 (s, 2H, CH2), 8.02 (brs, 1H, NH),
13.00 (brs, 1H, NH)
10% (V/V) Tween 80 suspension intraperitonially. One group was administered acetyl-
salicylic acid intraperitoneally in a dose of 200 mg kg–1 once daily for 3 days. The
remaining groups of animals were administered test compounds intraperitoneally in a
dose of 20 mg kg–1. On the fourth day, pylorus was ligated as per the method of Shay et
al. (19); animals were fasted for 36 h before the pylorus ligation procedure. Four hours
after the ligation, animals were sacrificed. The stomach was removed and opened along
the greater curvature. Ulcer index was determined by the method of Ganguly and Bhat-
nagar (20) and is given in Table V.
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1H NMR (d, ppm)
(DMSO-d6)





1.03 (d, 6H, 2CH3), 2.02 (Septet, 1H, CH), 2.39 (s,
3H, CH3), 2.48 (s, 2H, CH2), 8.60 (brs, 2H, 2NH,
D2O exchangeable), 13.20 (brs, 1H, NH)
8b 3397 (brs, 2NH)
1710 (C=O)
1360 (C=S)
1.02 (d, 6H, 2CH3), 2.03 (Septet, 1H, CH), 2.41 (s,
3H, CH3), 2.51 (s, 2H, CH2), 8.45 (brs, 2H, 2NH),
13.30 (brs, 1H, NH)




1.00 (d, 6H, 2CH3), 2.00 (Septet, 1H, CH), 2.38 (s,
3H, CH3), 2.49 (s, 2H, CH2), 8.42 (brs, 2H, NH2),
13.20 (brs, 2H, NH2)




1.01 (d, 6H, 2CH3), 2.04 (Septet, 1H, CH), 2.40 (s,
3H, CH3), 2.50 (s, 2H, CH2), 8.23 (brs, 2H, NH2,
D2O exchangeable), 12.20 (brs, 1H, OH)





1.02 (d, 6H, 2CH3), 1.34 (t, 3H, CH3), 2.01 (Septet,
1H, CH), 2.41 (s, 3H, CH3), 2.52 (s, 2H, CH2), 3.89
(q, 2H, CH2), 8.00 (s, 1H, methylenic proton),
13.00 (brs, 1H, NH, D2O exchangeable)
11b 3385 (brs, NH)
2215 (CN)
1708 (C=O)
1.01 (d, 6H, 2CH3), 1.35 (t, 3H, CH3), 2.00 (Septet,
1H, CH), 2.11 (s, 3H, CH3), 2.43 (s, 3H, CH3), 2.53
(s, 2H, CH2), 3.91 (q, 2H, CH2), 13.10 (brs, 1H,
NH)
12 3420 (brs, NH2)
2216 (CN)
1708 (C=O)
1.03 (d, 6H, 2CH3), 2.00 (Septet, 1H, CH), 2.40 (s,
3H, CH3), 2.51 (s, 2H, CH2), 8.16 (s, 1H, methyl-
enic proton), 11.50 (brs, 2H, NH2, D2O exchange-
able)
13 249 (M+) (100) 3410 (brs, NH2)
1704 (C=O)
1.00 (d, 6H, 2CH3), 2.02 (Septet, 1H, CH), 2.39 (s,
3H, CH3), 2.50 (s, 2H, CH2), 8.32 (s, 1H, pyrimi-
dine proton), 11.50 (brs, 2H, NH2, D2O exchange-
able)






1.04 (d, 6H, 2CH3), 2.03 (Septet, 1H, CH), 2.42 (s,
3H, CH3), 2.53 (s, 2H, CH2), 8.28 (s, 1H, pyrimi-




According to Gewald et al. (11), heating under stirring of a mixture of ethylcyano-
acetate, sulfur, benzylmethyl ketone and diethylamine in absolute ethanol for 8 hours af-
forded 2-amino-4-methyl-5-phenyl-thiophene-3-ethylcarboxylate 1 (85%). The latter com-
pound was cyclized by refluxing in a mixture of potassium thiocyanate and dioxane in
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Table III. Percent anti-inflammatory activity of test compoundsa,b,c
Compd.

























































































































































































a Vehicle: 1 mL 10% (V/V) Tween-80. Dose: 15 mg kg–1 b.m. test compound and 10 mg kg–1 b.m. of indomethacin.
b Values represent the mean ± SEM (n = 6).
c Each value in parentheses indicates the percentage inhibition rate.
d The potency (pot.) was calculated compared to the reference drug indomethacin.
e Significantly different from control (Dunnett’s test): p < 0.05.
f Significantly different from indomethacin (Dunnett’s test): p < 0.05.
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Table IV. Peripheral analgesic activitya
Compd. No. of writhes in 20 min Protection (%)
Control 48.0 ± 2.2d 0
4a 23.2 ± 1.4c 52
4b 31.0 ± 1.6c,d 35
4c 30.2 ± 1.7c,a 37
4d 31.0 ± 1.6c,d 35
4e 41.3 ± 2.4d 14
4f 45.2 ± 1.8d 6
5a 31.3 ± 2.5c,d 35
5b 19.6 ± 0.5c 59
6 19.0 ± 1.2c 60
7 19.6 ± 0.5c 59
8a 45.8 ± 2.9d 5
8b 45.8 ± 2.9d 5
Acetylsalicylic acid 22.6 ± 2.0c 53
a Vehicle: 1 mL of distilled water. Dose: 15 mg kg–1 b.m. of test compound and 100 mg kg–1 b.m.
of acetylsalicylic acid.
b Values represent the mean ± SEM (n = 6).
c Significantly different from control (Dunnett’s test): p < 0.05.
d Significantly different from acetylsalicylic (Dunnett’s test): p < 0.05.
Table V. Ulcerogenicity index
Compd. Ulcer idex
Control 0.9 ± 0.1c
4a 1.1 ± 0.3d
4b 0.9 ± 0.3c
4c 1.2 ± 0.3d
4d 0.7 ± 0.2c
4e 1.1 ± 0.2d
4f 0.8 ± 0.2c
5a 0.9 ± 0.2c
5b 1.1 ± 0.2d
6 1.1 ± 0.2d
7 0.9 ± 0.3c
8a 0.9 ± 0.2c
8b 1.1 ± 0.3
Acetylsalicylic acid 1.7 ± 0.4d
a Vehicle: 1 mL of 10% (V/V) of Tween-80. Dose: 20 mg kg–1 b.m. of
test compound and 200 mg kg–1 b.m. of acetylsalicylic acid.
b Each value represents the mean ± SEM (n = 6).
Significantly different from acetylsalicylic acid: c p < 0.05, d p < 0.01.
the presence of concentrated hydrochloric acid affording 5-methyl-6-phenyl-2-thioxo-
-thieno[2,3-d]pyrimidine derivative 2 (Scheme 1). The 1H NMR spectrum of the resulting
product 2 is in agreement with the given structure and literature (21). Stirring a mixture
of malononitrile, 6-methyl-heptane-2,4-dione, sulfur and diethylamine in absolute ethanol
afforded acetone-1-(2-amino-5-isopropyl-thiophene-3-carbonitrile derivative 3 (73%) (Sche-
me 1). Also, the latter compound was used as a good source to enrich the synthesis of
heterocyclic chemistry with several new thieno-pyrimidines, thienothiazine and thieno-
pyridine derivatives.
As part of our continuing program on the synthesis of various functionalized mono-
-heterocyclic and annelated heterocyclic derivatives (22, 23), we report here a new syn-
thetic strategy for the preparation of functionalized thieno[2,3-d][1,2,4]-5H-1,3-disub-
stituted-triazolo[4,3-a]pyrimidine-5-one derivatives 4a–f via reactions of hydrazonoyl
chlorides with 5-methyl-6-phenyl-2-thioxo-thieno[2,3-d]pyrimidine (2) (Scheme 2). Beside
the correct values of elemental analysis, the IR, 1H NMR and mass spectra of compounds
4a–f are in agreement with the assigned structures. The N-3 nitrogen atom and not the
N-1 nitrogen atom was involved in the cyclization to form adduct 4 and not isomer 4’.
2-Amino-5-isopropyl-4-(2-oxo-propyl)-thiophene-3-carbonitrile (3) behaved as a ty-
pical -enaminonitrile derivative due to the presence of amino and carbonitrile groups
at positions 2 and 3, respectively, attached to the thiophene ring, which is considered as
a precursor in the synthesis of various heterocyclic derivatives with several new azolo-
thienopyrimidines, thienothiazine and thienopyrimidines (24). Therefore, heating under
reflux of compound 3 with aliphatic acids, namely, formic and acetic acids for 6 hours
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yielded thieno[2,3-d]-pyrimidin-4-one (5a,b) (Scheme 3). Besides, the correct values of el-
emental analyses, the 1H NMR spectrum, IR and mass spectra of the new compounds
were in agreement with the assigned structures.
Similarly, compound 3 reacted with carbon disulphide in the presence of potassium
hydroxide in absolute ethanol to yield 1-(6-isopropyl-2,4-dithioxo-1,2,3,4-tetrahydro-thieno-
[2,3-d]pyrimidin-5-yl)-propan-2-one (6). IR spectrum of 6 displayed absorption bands at
1350 and 1365 cm–1 of two C=S groups. On the other hand, stirring under reflux of com-
407
A.-R. B. A. El-Gazzar et al.: Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic























































































R = Ar = R = COCH , Ar = -C H -NOa: d: pC H6 5 3 6 4 2
R = COCH , Ar = -C H -Cl R = COOC H , Ar = C Hb: e:p3 6 4 2 5 6 5
R = COCH , Ar = -C H -OCH R = COOC H , Ar = -C H -CHc: f:p p3 6 4 3 2 5 6 4 3
Scheme 2
pound 3 with carbon disulphide in dry pyridine afforded the 1-(4-imino-6-isopropyl-
2-thioxo-1,4-dihydro-2H-thieno[2,3-d][1,3]thiazin-5-yl)-propan-2-one (7). Also, when heated
with urea or thiourea at 180 °C, compound 3 gave 4-amino-6-isopropyl-5-(2-oxo-propyl)-
-1H-thieno[2,3-d]pyrimidin-(2-one or 2-thione) derivatives 8a,b, respectively (Scheme 3).
When compound 3 was reacted with active methylenes, malononitrile in glacial acetic
acid and ethylcyanoacetate in dry dioxane in the presence of catalytic amount of tri-
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ethylamine, it yielded the corresponding 4,6-diamino-2-isopropyl-3-(2-oxo-propyl)-thieno-
-[2,3-b]pyridine-5-carbonitrile (9) and 4-amino-6-hydroxy-2-isopropyl-3-(2-oxo-propyl)-
-thieno[2,3-b]pyridine-5-carbonitrile (10), respectively (Scheme 3). Structures 9 and 10
were tentatively preferred for this product based on its 1H NMR spectrum and the IR
spectra, which revealed the presence of the cyano-group around 2212 cm–1 and NH2
group around 3500 cm–1. Condensation of 3 with triethyl orthoformate or triethylortho-
acetate in boiling acetic anhydride yielded the corresponding N-[3-cyano-5-isopropyl-4-
-(2-oxo-propyl)-thiophen-2-yl]-formamidic acid ethyl ester (11a) and N-[3-cyano-5-isopropyl-
-4-(2-oxo-propyl)-thiophen-2-yl]-acetimidic acid ethyl ester (11b) respectivly, with com-
patible IR and 1H NMR data. Compound 11a reacted with ammonium hydroxide solution
in absolute ethanol to give N-[3-cyano-5-isopropyl-4-(2-oxo-propyl)-thiophen-2-yl]-for-
mamidine (12), which on boiling in absolute ethanolic sodium ethoxide solution under-
went cyclization to give 1-(4-amino-6-isopropyl-thieno[2,3-d]-pyrimidin-5-yl)-propan-2-
-one (13) (Scheme 3). The IR spectrum of 12 displayed an absorption band at 2216 cm–1 (CN),
while, that of 13 revealed the absence of CN group. Finally, stirring compound 11a with
hydrazine in absolute ethanol at room temperature gave 1-(3-amino-4-imino-6-isopropyl-
-3,4-dihydro- thieno[2,3-d]pyrimidin-5-yl)-propan-2-one (14).
The anti-inflammatory activity data (Table III) indicated that all the test compounds
protected rats from carrageenean induced inflammation. Compounds 4a, 4b, 4e, 5b, 6
and 7 protected rats by 36 to 56% from inflammation while the other tested compounds
showed lower anti-inflamatory activity in comparison to indomethacin. This means that
the fused triazolo[4,3-a]pyrimidine, pyrimidine-2,4-dithione and thieno[2,3-d][1,3]thiazine
possess good anti-inflammatory activity.
The results of analgesic activity indicate that all the test compounds exhibited high
activity (Table IV). Triazolo[4,3-a]pyrimidine 4a with triphenyl substitution showed high
activity comparable to that of acetylsalicylic acid. The compounds with acetyl or ethyl-
ester group substitution (4b–d), showed moderate activity. Also, thieno[2,3-d]pyrimidin-
es 5b and 6 and thieno[2,3-d][1,3]thiazin 7 were found to be the most active analgesic
agents, even more potent than acetylsalicylic acid.
The ulcer index of the test compounds (Table V) reveals that all compounds showed
a mild ulcer index as compared to acetylsalicylic acid.
CONCLUSION
New compounds, substituted thieno[2,3-d][1,2,4]-triazolo[4,3-a]pyrimidin-5-ones
4a, 4b, 4e 6-isopropyl-2-methyl-5-(2-oxo-propyl)-3H-thieno[2,3-d] pyrimidin-4-one (5b),
1-(6-isopropyl-2,4-dithioxo-1,2,3,4-tetrahydro-thieno[2,3-d] pyrimidin-5-yl)propan-2-one
(6) and 1-(4-imino-6-isopropil-2-thioxo-1,4-dihydro-2H-thieno[2,3-d][1,3]thiazin-5-yl)pro-
pan-2-one (7) showed moderate anti-inflammatory activity. However, thieno[2,3-d][1,2,4]-
triazolo[4,3-a]pyrimidin-5-ones 4a–d and 6-isopropyl-5-(2-oxo-propyl)-3H-thieno[2,3-d]
pyrimidin-4-one (5a) and compounds 5b, 6 and 7 showed good to excellent analgesic
activity.
409
A.-R. B. A. El-Gazzar et al.: Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic
and ulcerogenic activity, Acta Pharm. 57 (2007) 395–411.
REFERENCES
1. D. J. Brown, Pyrimidines and Their Benzo Derivatives, in Comprehensive Heterocyclic Chemistry (Ed.
A. R. Katritzky and C. W. Rees), Vol. 3, Pergamon Press, Oxford 1984, p. 443.
2. B. Roth and C. Cheng, Diaminopyrimidines, in Progress in Medicinal Chemistry (Eds. G. B. Ellis
and G. E. West), Vol. 19, Elsevier Biomedical Press, New York 1982, p. 267.
3. M. S. A. E.-A. El-Gaby, S. G. Abdel-Hamide, M. M. Ghorab and S. M. El-Sayed, Synthesis and
anticancer activity in vitro of some new pyrimidines, Acta Pharm. 49 (1999) 149–158.
4. C. R. Petrie, H. B. Cottam, P. A. Mckernan, R. K. Robins and G. R. Revankar, Synthesis and bio-
logical activity of 6-azacadeguomycin and certain 2,4,6-trisubstituted pyrazolo[3,4-d]-pyrimidine
ribonucleosides, J. Med. Chem. 28 (1985) 1010–1016.
5. M. N. Nasr and M. M. Gineinah, Pyrido[2,3-d]pyrimidines and pyrimido[5’,4’:5,6]-pyrido[2,3-d]
pyrimidines as new antiviral agents: Synthesis and biological activity, Arch. Pharm. 335 (2002)
289–295; DOI: 10.1002/1521-4184(200208)335:6289.
6. P. G. Baraldi, M. G. Pavani, M. Nunez, P. Brigidi, B. Vitali, R. Gambari and R. Romagnoli, Anti-
microbial and antitumor activity of N-heteroimine-1,2,3-diathiazoles and their transformation
in triazolo-, imidazo- and pyrazolopyrimidines, Bioorg. Med. Chem. 10 (2002) 449–456; DOI: 10.
1016/S0968-0896(01)00294-2.
7. S. M. Sondhi, M. Johar, S. Rajvanshi, S. G. Dastidar, R. Shukla, R. Raghubir and J. W. Lown,
Anticancer, anti-inflammatory and analgesic activity evaluation of heterocyclic compounds syn-
thesized by the reaction of 4-isothiocyanato-4-methylpentan-2-one with substituted o-phenyl-
enediamines, o-diaminopyridine and (un)substituted o-diamino-pyrimidines, Australian J. Chem.
54 (2001) 69–74; DOI: 10.1071/CH00141.
8. A. Z. M. S. Chowdhury, M. M. Matin and M. N. Anwar, Synthesis and antimicrobial activities of
fused pyrimidines: Benzothieno[2,3-d]imidazol[1,2-c]pyrimidine, Chittagong Univ. Stud. Part II
21 (1997) 79–83; ref Chem. Abstr. 130 (1999) 237530p.
9. A. M. Abdel-Fattah, A. S. Aly, F. A. Gad, M. E. A. Zaki and A. B. A. El-Gazzar, A facile synthesis
of isooxazolo[5,4:4’,5’]thiazolo[3,2-a]thienopyrimidines, a new ring system, Phosphorus Sulfur
141 (1998) 263–281; DOI: 10.1080/10426509808033738.
10. A. M. Abdel-Fattah, A. S. Aly, F. A. Gad, N. A. Hassan and A. B. A. El-Gazzar, Synthesis and re-
action of polynuclear heterocycles, with a new ring system, Phosphorus Sulfur 163 (2000) 1–27;
DOI: 10.1080/10426500008046607.
11. A. K. Gewald, E. Schinke and H. Bottcher, 2-Amino-thiophene aus methylenaktiven Nitrilen,
Carbonylverbindungen und Schwefel, Chem. Ber. 99 (1966) 94–100.
12. P. Wolkoff, T. S. Nemeth and S. M. Gibson, Reaction of hydrazonyl halides with derivatives of
thiourea and thiosemicarbazide; A new source of C-amino- and C-hydrazino-1,2,4-triazoles,
Can. J. Chem. 53 (1975) 3211–3215.
13. A. F. Hegarty, M. Cashoman, J. B. Aylward and F. L. Scott, Ortho-group participation in azo-
carbonium ion and 1,3-dipolar ion formation, J. Chem. Soc. B 57 (1971) 1879–1883.
14. Guide to the Care and Use of Experimental Animals, Vol. 1, 2nd ed. (Eds. E. D. Olfert, B. M. Cross
and A. A. McWilliam), Canadian Council of Animal Care, Ottawa 1993.
15. C. A. Winter, E. A. Risley and G. W. Nuss, Carrageenin-induced edema in hind paw of the rats
as an assay anti-inflammatory drugs, Proc. Soc. Exp. Biol. Med. III (1962) 544–547.
16. J. Miño, V. Moscatelli, O. Hnatyszyn, S. Gorzalczany, C. Acevedo and G. Ferraro, J. Pharmacol.
Res. 50 (2004) 59–63; DOI: 10.1016/j.phrs.2003.12.016.
17. H. D. J. Collier, L. C. Dinnin, C. A. Johnson and C. Schneider., The abdominal response and its
suppression by analgestic drugs in the mouse Br. J. Pharmacol. Chemother. 32 (1968) 295–310.
18. R. K. Goel, A. Chakrabarthi and A. K. Sanyal, Planta Med. 29 (1985) 85–88.
410
A.-R. B. A. El-Gazzar et al.: Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic
and ulcerogenic activity, Acta Pharm. 57 (2007) 395–411.
19. H. Shay, S. A. Komarav, S. E. Fels, D. Meraza, M. Gruenstein and H. Siplet, Gastroenterology 5
(1994) 43–61.
20. A. K. Ganguly and O. P. Bhatnagar, Can. J. Physiol. Pharmacol. 51 (1973) 748–750.
21. A. M. Abdel-Fattah, A. S. Aly, F. Abdel-Motti, N. A. Hassan and H. A. Aly, Synthesis and reaction
of some thienopyrimidine derivatives and some of photooxidation, Egyptian J. Chem. 38 (1995)
627–633.
22. A. S. Aly, A. B. A. El-Gazzar and H. A. R. Hussien, Synthesis and reactions of polynuclear he-
terocycles: Azolothienopyrimidines and thienothiazolopyrimidines, Phosphorus Sulfur 181 (2006)
2771–2784; DOI: 10.1080/10426500600865293.
23. A. B. A. El-Gazzar, H. A. R. Hussien and A. S. Aly, Synthesis of some derivatives derived from
1,2,3,4-tetrahydrocyclo-hepteno[4,5]thieno[2,3-d]pyrimidine, Phosphorus Sulfur 182 (2007) 35–56;
DOI: 10.1080/10426500600864536.
24. B. Cacciari and G. Spalluto, Facile and versatile route to the synthesis of fused 2-pyridones:
Useful intermediates for polycyclic systems, Synthetic Commun. 36 (2006) 1177–1183; DOI: 10.
1080/00397910500514063.
S A @ E T A K
Sinteza i protuupalno, analgetsko i ulcerogeno djelovanje
derivata tieno[2,3-d]pirimidina
ABDEL-RAHMAN B. A. EL-GAZZAR, HODA. A. R. HUSSEIN i HEND. N. HAFEZ
Reakcijom derivata 5-metil-6-fenil-2-tioksotieno[2,3-d]pirimidona (2) s hidrazonoil klo-
ridima dobiveni su triazolotienopirimidoni 4a–f, a reakcijom aceton-1-(2-amino-5-izopropil-
-tiopen-3-karbonitrila (3) s funkcionalnim i bifunkcionalnim spojevima dobiveni su pro-
dukti 511. Novi spojevi imaju sli~no protuupalno, analgetsko i ulcerogeno djelovanje
kao i indometacin, odnosno acetilsalicilna kiselina.
Klju~ne rije~i: triazolotienopirimidin, tienopirimidini, tieno[2,3-d][1,3]tiazin, tienopiridini, analgetsko,
protuupalno, ulcerogeno djelovanje
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